bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.03.09.642289

Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas

Ali, H.·Zhou, N.·Chen, L.·Hijfte, L. v.·Karri, V.·Zhou, Y.·Habashy, K.·Arrieta, V. A.·Kim, K.-S.·Duffy, J.·Yeeravalli, R.·Tiek, D.·Song, X.·Mishra, S.·Lee-chang, C.·Ahmed, A. U.·Heiland, D. H.·Sonabend, A. M.·Dmello, C.
View original source ↗Export metadata ↓

Abstract

Although GBMs immunosuppressive environment is well known, the tumors resistance to CD8+ T cell killing is not fully understood. Our previous study identified Checkpoint Kinase 2 (Chek2) as the key driver of CD8+ T cell resistance in mouse glioma through an in vivo CRISPR screen and demonstrated that Chk2 inhibition, combined with PD-1/PD-L1 blockade, significantly enhanced CD8+ T cell-mediated tumor killing and improved survival in preclinical model. Here, we aimed to elucidate the immunosuppressive function of Chek2. Immunoprecipitation (IP) followed by mass spectrometry (MS) and phosphoproteomics identified an association between Chek2 with the DNA/RNA-binding proteins YBX1 and YBX3 that are implicated in transcriptional repression of pro-inflammatory genes. Single-gene knock-out and overexpression studies of CHEK2, YBX1, and YBX3 in multiple glioma cell lines revealed that these proteins positively regulate each others expression. RNA sequencing coupled with chromatin immunoprecipitation-sequencing (ChIP-seq) analysis demonstrated common inflammatory genes repressed by CHK2-YBX1&YBX3 hub. Targeting one of the hub proteins, YBX1, with the YBX1 inhibitor SU056 led to degradation of CHK2-YBX1&YBX3 hub. Targeting of this hub by SU056 led to enhanced antigen presentation and antigen specific CD8+ T cell proliferation. Further, combination of SU056 with ICB significantly improved survival in multiple glioma models. Collectively, these findings reveal an immunosuppressive mechanism mediated by the CHK2-YBX1&YBX3 hub proteins. Therefore, CHK2-YBX1&YBX3 hub targeting in combination with immune checkpoint blockade therapies in gliomas is warranted.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ali, H., Zhou, N., Chen, L., Hijfte, L. v., Karri, V., Zhou, Y., Habashy, K., Arrieta, V. A., Kim, K.-S., Duffy, J., Yeeravalli, R., Tiek, D., Song, X., Mishra, S., Lee-chang, C., Ahmed, A. U., Heiland, D. H., Sonabend, A. M., Dmello, C.. 2025-03-13. Targeting CHEK2-YBX1&YBX3 regulatory hub to potentiate immune checkpoint blockade response in gliomas. https://doi.org/10.1101/2025.03.09.642289

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Regulation of the Epstein-Barr Epigenome by Histone Variant MacroH2A

Histone variants play an important role in regulating chromatin dynamics of Epstein-Barr Virus (EBV). Here, we investigate the role of histone variant macroH2A in EBV chromatin structure, gene expression and copy number control during latent infection. ChIP-seq analysis in EBV+ SNU719 gastric carcinoma and Mutu I Burkitt lymphoma cells revealed that macroH2A was most enriched at repetitive DNA elements, including oriLyt, BHLF1, LF3 and terminal repeat (TR) regions of the EBV genome. MacroH2A depletion in EBV-associated gastric cancer cell line SNU719 led to a small increase in some viral lytic genes and increase in viral DNA copy number. RNAseq transcriptomics after macroH2A depletion identified major perturbations in cellular gene pathways, including beta-catenin/TCF signaling and chromatin remodeling. Depletion of macroH2A during EBV lytic reactivation reduced EBV lytic gene activation, but increased EBV DNA copy number. Previous study demonstrated a colocalization and cooperative binding between histone variant H2A.Z and EBNA1. We now show that depletion of macroH2A causes an increase in both H2A.Z and EBNA1 at oriP and cellular binding sites for EBNA1. We also found that gammaH2AX localizes to oriP and that this depends on macroH2A. Finally, we show that CRISPR/Cas9 knockout of macroH2A increases the replication and episome maintenance of oriP-containing plasmids. Taken together, these findings indicate that macroH2A localizes to the repetitive elements of EBV, including oriLyt, and can function to limit H2A.Z and EBNA1 binding at oriP, which alters DNA damage signaling at oriP and limits episomal replication. These findings provide a novel role for macroH2A in maintaining EBV copy number and genome integrity.

cancer biology↗
bioRxiv2026

Epigenomic circuits shaping cellular heterogeneity in pleural mesothelioma

Pleural mesothelioma (PM) is an aggressive and lethal malignancy with current treatments offering limited clinical benefit. In this study, we utilized single-cell chromatin accessibility and transcriptomic profiling of patient-matched samples to infer the epigenomic regulation underlying cellular heterogeneity in PM. High-resolution epigenomic profiling suggested transcriptional regulators with putative pro-tumoral roles in mesothelioma, whose function was experimentally tested using genetic perturbations across four PM cell lines. Furthermore, we observed several putative associations between epigenomic circuits and macrophage ontogeny, a sarcomatoid-like neoplastic state, and a fetal-like endothelial cell state. Our analysis also showed similarities between the chromatin accessibility landscapes of exhausted CD8 T and KLRC1 natural killer cells and identified NR4A2 as a potential shared regulator of dysfunction in both lymphocyte subsets. We further identified a state-specific distal enhancer near NR4A2 and experimentally validated its regulation of NR4A2 expression in Jurkat cells. Together, we provide an epigenomic map of PM and nominate candidate transcription factors and regulatory elements for future functional investigation, including their potential relevance to epigenetic editing strategies to limit tumor growth and enhance anti-tumor immunity.

cancer biology↗
bioRxiv2026

Multimodal Liquid Biopsy Improves Longitudinal Circulating Tumor DNA Detection in Children with Central Nervous System Tumors

Background: Circulating tumor DNA (ctDNA) is a promising biomarker for pediatric central nervous system (CNS) tumors, but limitations in sensitivity and universally accepted detection criteria remain. We evaluated multimodal ctDNA detection using a novel composite scoring framework integrating mutation, copy number, and fragmentomic analysis in longitudinal plasma and CSF samples from children with CNS tumors. Methods: Tumor, blood and/or CSF samples were collected from pediatric CNS tumor patients. DNA was extracted from plasma, CSF, tumor, and whole blood. All samples underwent targeted and whole genome sequencing. Plasma and CSF samples were evaluated for ctDNA positivity--defined by a composite score [≥]2--utilizing a tri-modal approach of whole genome sequencing for copy number alterations and fragmentomics and targeted sequencing. Results: The cohort included 28 patients: medulloblastoma (39%), diffuse midline glioma (25%), high-grade glioma (18%), pilocytic astrocytoma (11%), and ependymoma (7%). A total of 140 plasma and 27 CSF samples were collected longitudinally. Combining all three modalities identified ctDNA in 70% of CSF and 17% of plasma samples, exceeding rates achieved by any single modality alone. Post-diagnosis plasma ctDNA positivity was significantly associated with worse progression-free and overall survival. CSF demonstrated significantly higher ctDNA signal intensity than plasma across all assay modalities. Conclusions: A multimodal composite scoring approach improves longitudinal ctDNA detection in pediatric CNS tumors. Although CSF remains the most sensitive biofluid, plasma ctDNA reflects disease progression in select patients. These findings support integrated, multimodal liquid biopsy strategies for disease monitoring and highlight the need for prospective validation of standardized detection criteria.

cancer biology↗